• J. Neurol. Sci. · May 2018

    Clinical Trial Observational Study

    Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures.

    • Robert Zivadinov, Niels Bergsland, Jesper Hagemeier, Ellen Carl, Hanna Kolb, David Hojnacki, and Bianca Weinstock-Guttman.
    • Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, NY, USA; Center for Biomedical Imaging at the Clinical Translational Science Institute, University at Buffalo, State University of New York, NY, USA. Electronic address: rzivadinov@bnac.net.
    • J. Neurol. Sci. 2018 May 15; 388: 175-181.

    ObjectivesTo investigate the effect of teriflunomide on microstructural pathology in the gray matter (GM) and white matter (WM), as measured by changes in brain volume and diffusion-tensor imaging (DTI) in patients with multiple sclerosis (MS).Methods30 relapsing MS patients and 20 healthy controls (HCs) were enrolled in the study and followed prospectively for 12 months with clinical and 3T MRI examinations. Of those, 26 MS patients and 18 HCs completed the 6-month and 22 MS and 16 HCs patients the 12-month follow-up. Whole brain, GM, WM and thalamus volumes, and global and tract-based spatial statistics (TBSS) DTI measures of fractional anisotropy, mean, axial and radial diffusivity were obtained in the thalamus and normal appearing WM (NAWM). MRI differences between the groups were compared using non-parametric statistical methods due to sample size limitations, followed by post-hoc covariate-adjusted models.ResultsAt baseline, MS patients showed more severe brain volume and DTI measures compared to HCs (p < .05). At follow-up, no significant differences for brain volume and global and TBSS DTI measures between MS patients and HCs were found. No clinical progression or serious adverse events occurred in MS patients over the follow-up.ConclusionsMS patients did not significantly deteriorate over the follow-up in brain volume or thalamus/NAWM global or TBSS DTI measures, compared to HCs. This suggests that treatment with teriflunomide could potentially slow down accumulation of microstructural tissue damage in the GM and NAWM.Copyright © 2018 Elsevier B.V. All rights reserved.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.